In Q4 2017, the FDA granted priority review for AbbVie's NDA for endometriosis. The FDA grants priority review to medicines it determines have potential to provide significant improvements in the safety and effectiveness of the treatment of a serious disease. If approved, elagolix will be the first new oral medical management treatment option for endometriosis-associated pain in more than a decade.
AbbVie and Neurocrine Biosciences Announce PDUFA Target Date of Q3 2018 for Elagolix in Endometriosis-Associated Pain
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться